retatrutide mechanism triple agonist glp-1 gip glucagon Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Major physiological roles of GLP-1

These findings, revealed more than a decade after the first approval of twice-daily exenatide in 2005, have rekindled enthusiasm for the use of GLP-1R agonists, alone or in combination, in the treatment of T2D and obesity, most compellingly in subjects at high risk for cardiovascular disease

When the math doesnt add up But those benefits come at a price: roughly $700-800 per month in the U.S

K., Mocanu, M

Eligibility typically depends on income and insurance status

All of these findings are consistent with the concept that GLP-1 receptor agonists inhibit eating and reduce body weight primarily by acting directly in the brain, and that various brain areas are involved in mediating the eating-inhibitory effects of GLP-1 receptor agonists

He L, Wong CK, Cheung KK, et al